BIOLINERX
Careers | Contact Us
search

Press Releases
November 1, 2018
Management to hold conference call at 10:00 a.m. EST
October 20, 2018
Results presented today demonstrate that BL-8040 significantly improves T-cell infiltration into the tumor and reduces immunosuppression in the tumor microenvironment

October 19, 2018
BL-8040 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer

Encouraging results support further development of combination
and expansion of collaboration

Triple combination expansion cohort (BL-8040 + KEYTRUDA® (pembrolizumab) + chemotherapy) to commence by year-end

October 3, 2018
Transaction increases BioLineRx’s stake by 20%, to 80%, ahead of numerous potential value-creating milestones 

Top-line results from ongoing Phase 2a pancreatic cancer study in combination with KEYTRUDA® expected this quarter

Management to hold conference call today, October 3, at 10:00 am EDT

August 7, 2018
Data from first lead-in patient cohort prompts Data Monitoring Committee to
recommend early continuation to randomized placebo-controlled part 2 of trial

August 6, 2018
Management to hold a conference call at 10:00 a.m. EDT
1-10  Out of  297
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30 
Next